Sector News

Pfizer’s John Davis splashes into biotech as Magenta CMO

February 26, 2018
Life sciences

Magenta Therapeutics has appointed a new chief medical officer: John Davis, M.D., who was previously a senior vice president and head of early clinical development at Pfizer.

The startup, which raised $50 million in series B funding last May, is working on targeted therapeutics to make stem cell transplants safer and more effective. It has programs addressing patient preparation for transplants, stem cell harvesting, stem cell expansion and post-transplant complications.

“As a clinical stage company, we are delighted to welcome John, a very seasoned physician-scientist, to our team,” said Magenta CEO Jason Gardner in a statement. “John’s rich experience in immunology and drug development will be crucial as we move our programs forward.”

Before heading early clinical development at Pfizer, Davis served stints at Baxalta and Genentech and spent nearly 10 years on the faculty at UC San Francisco conducting research in autoimmune disease.

Magenta’s lead candidate, MGTA-456, is designed to expand the number of stem cells in cord blood used for transplant. The biotech licensed the drug, formerly known as HSC835, from Novartis in May, gaining the rights to use it in “selected applications.” It is developing the drug for multiple diseases, including immune and blood disorders.

The biotech announced a second deal at the same time, with Be the Match BioTherapies (BTMB), which is working on delivering autologous and allogeneic cellular therapies. The collaboration allows Magenta to use BTMBs’ cell therapy delivery platform, industry relationships, clinical trial design and management, and patient outcomes data.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).